BECLAZONE

This brand name is authorized in Cyprus, Estonia, Hong Kong, Ireland, New Zealand

Active ingredients

The drug BECLAZONE contains one active pharmaceutical ingredient (API):

1 Beclometasone UNII 5B307S63B2 - BECLOMETHASONE DIPROPIONATE

Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. Read about Beclometasone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BECLAZONE 250mg Pressurised inhalation, solution	Υπουργείο Υγείας (CY)	MPI, EU: SmPC
BECLAZONE 100mg Pressurised inhalation, solution	Υπουργείο Υγείας (CY)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03BA01	Beclometasone	R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BA Glucocorticoids
Discover more medicines within R03BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1689587
Country: HK	Department of Health Drug Office	Identifier(s): 43841, 43844
Country: IE	Health Products Regulatory Authority	Identifier(s): 13926, 13952, 13967, 13978, 14091, 14111, 14122
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11203, 11204, 11205